Novo Nordisk Raises Adjusted Sales And Adjusted Operating Profit Outlook For 2026 - GNW

Q2 2026 Adj Sales DKK78.49 Bln; Adj Oper Profit DKK33.39 Bln - Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER - Outlook FY Adjusted EBIT Growth -6 To 0% - Outlook FY Adjusted Revenue Growth -6 To 0% - Raises 2026 Adj Sales And Oper Profit Outlook To 0% To -6% At CER - Improved Outlook Is Driven By Increased Expectations For GLP-1 Product Sales - DKK6.3 Bln Non-Recurring, Non-Cash Impairment Charges In Q2 Related To Intangible Pipeline Assets